News

Pharmaceutical News

Pharmaceutical News

FDA Approves Selexipag for Pulmonary Arterial Hypertension

  • Date: 01-07-2016 --
  • 12/30/15, The Pharmaceutical Journal
  • body: The U.S. Food and Drug Administration (FDA) has approved selexipag to treat adults with pulmonary arterial hypertension (PAH), a chronic and progressive lung disease that causes high pressure in the arteries that connect the heart to the lungs. The drug, marketed as Uptravi by Actelion Pharmaceuticals, is an oral prostacyclin receptor (IP) agonist. It is indicated to delay disease progression and reduce the risk of hospital admission for PAH.
  • URL: http://multibriefs.com/ViewLink.php?i=568d2aee7fc5f